about
The risk of ischaemic stroke in primary antiphospholipid syndrome patients: a prospective study.Severe Multi-Organ Failure and Hypereosinophilia: When to Call It "Idiopathic"?Infodemiology of antiphospholipid syndrome: Merging informatics and epidemiologyIs air pollution affecting the disease activity in patients with systemic lupus erythematosus? State of the art and a systematic literature reviewGlobal antiphospholipid syndrome score and anti-ß2-glycoprotein I domain I for thrombotic risk stratification in antiphospholipid syndrome: A four-year prospective studyComparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repositoryAnti-beta-2-glycoprotein I domain 1 identifies antiphospholipid antibodies-related injuries in patients with concomitant lupus nephritisFilling the gap in antiphospholipid syndrome diagnosis: a patient's storyTailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTORApp-A Usability StudyCD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyondLow ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients
P50
Q45873735-19E7D514-865E-4CAB-AFDB-D5C46676D7A8Q50324439-8E5A5410-F93A-41F0-8E91-CBA1CABF6600Q64043321-F3C9547D-564F-4E42-B766-65DEAFE43C2EQ89547149-B5387AC4-9C02-41F2-AA35-A131CE985CE1Q91834929-EABEA2B1-7EE2-4038-B7C1-0AC9331316A4Q92304261-C7E51C97-8476-4896-8A65-200D2A6F38B6Q92892946-AAB0E6A9-E08D-462E-BB08-54E9ACDEB34EQ93035212-4A0A1966-C4FE-4A33-A23C-57B5B5651F2EQ95321946-71199544-7579-4029-A33F-5F24B9EB43E1Q96344820-614EFDAE-B9B8-41B9-AC89-B00C0CD14DD7Q96583551-0A03F9DB-9D4D-4A5D-A562-667180C6EA7F
P50
description
researcher
@en
name
Savino Sciascia
@en
type
label
Savino Sciascia
@en
prefLabel
Savino Sciascia
@en
P31
P496
0000-0003-1266-9441